Seizure laboratory findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
Line 20: Line 20:
===Serum Prolactin Level===
===Serum Prolactin Level===


*A study found that:<ref name="pmid14988379">{{cite journal| author=Ahmad S, Beckett MW| title=Value of serum prolactin in the management of syncope. | journal=Emerg Med J | year= 2004 | volume= 21 | issue= 2 | pages= e3 | pmid=14988379 | doi=10.1136/emj.2003.008870 | pmc=1726305 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14988379  }} </ref>
One interpretation is the "prolactin should at least double and achieve a minimum value of 15 ng/mL in order to meet criteria for marking an epileptic seizure."<ref name="pmid29377043">{{cite journal| author=Fisher RS| title=Serum prolactin in seizure diagnosis: Glass half-full or half-empty? | journal=Neurol Clin Pract | year= 2016 | volume= 6 | issue= 2 | pages= 100-101 | pmid=29377043 | doi=10.1212/CPJ.0000000000000228 | pmc=5720615 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29377043  }} </ref>
**If the serum [[prolactin]] level is more than three times the baseline (taken within one hour of the event and in the absence of test modifiers):  
 
***The patient is nine times more likely to have had a generalized tonic-clonic seizure (GTCS) compared to a pseudoseizure, and five times more likely to have had a GTCS compared to a nonconvulsive [[syncope]].
A [[meta-analysis]] in 2004 found that:<ref name="pmid14988379">{{cite journal| author=Ahmad S, Beckett MW| title=Value of serum prolactin in the management of syncope. | journal=Emerg Med J | year= 2004 | volume= 21 | issue= 2 | pages= e3 | pmid=14988379 | doi=10.1136/emj.2003.008870 | pmc=1726305 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14988379  }} </ref>
*Another study found that:<ref name="pmid16157897">{{cite journal| author=Chen DK, So YT, Fisher RS, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology| title=Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. | journal=Neurology | year= 2005 | volume= 65 | issue= 5 | pages= 668-75 | pmid=16157897 | doi=10.1212/01.wnl.0000178391.96957.d0 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16157897  }} </ref>
*If the serum [[prolactin]] level is more than three times the baseline (taken within one hour of the event and in the absence of test modifiers):  
**Elevated prolactin level may be helpful in differentiating GTCS or complex partial seizure from psychogenic nonepileptic seizures, only if the patient’s [[prolactin]] level is measured 10 to 20 minutes after a suspected seizure event (grade B).
**The patient is nine times more likely to have had a generalized tonic-clonic seizure (GTCS) compared to a pseudoseizure, and five times more likely to have had a GTCS compared to a nonconvulsive [[syncope]].
**Analysis of the serum [[prolactin]] level is not effective in distinguishing a seizure from [[syncope]].
 
**No conclusion could be established regarding serum [[prolactin]] changes following [[status epilepticus]], repetitive seizures, and [[neonatal]] seizures (Level U).
A review by the American Academy of Neurology in 2005 found:<ref name="pmid16157897">{{cite journal| author=Chen DK, So YT, Fisher RS, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology| title=Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. | journal=Neurology | year= 2005 | volume= 65 | issue= 5 | pages= 668-75 | pmid=16157897 | doi=10.1212/01.wnl.0000178391.96957.d0 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16157897  }} </ref>
* For GTCS versus pseudoseizure:
** Sensitivity: 60%
** Specificity: ''96%''
* Elevated prolactin level may be helpful in differentiating GTCS or complex partial seizure from psychogenic nonepileptic seizures, only if the patient’s [[prolactin]] level is measured 10 to 20 minutes after a suspected seizure event (grade B).
* Analysis of the serum [[prolactin]] level is not effective in distinguishing a seizure from [[syncope]].
* No conclusion could be established regarding serum [[prolactin]] changes following [[status epilepticus]], repetitive seizures, and [[neonatal]] seizures (Level U).
 
A cohort study in 2016 of patient ''in an epilepsy monitoring unit who has prolactin measured within 20 minutes'' found<ref name="pmid29377044">{{cite journal| author=Abubakr A, Wambacq I| title=Diagnostic value of serum prolactin levels in PNES in the epilepsy monitoring unit. | journal=Neurol Clin Pract | year= 2016 | volume= 6 | issue= 2 | pages= 116-119 | pmid=29377044 | doi=10.1212/CPJ.0000000000000232 | pmc=5720616 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29377044  }} </ref>:
* For diagnosis of generalized tonic-clonic seizure (GTCS)
** Sensitivity: ''100%''
** Specificity: 81%


==References==
==References==

Latest revision as of 06:47, 6 January 2022

Seizure Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Seizure from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Seizure laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Seizure laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Seizure laboratory findings

CDC on Seizure laboratory findings

Seizure laboratory findings in the news

Blogs on Seizure laboratory findings

Directions to Hospitals Treating Seizure

Risk calculators and risk factors for Seizure laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]

Overview

The laboratory tests for patients with seizure may include checking for: hypoglycemia, hyponatremia, uremia, and drug intoxication, and levels of ammonia, creatine kinase (CK), lactate, and prolactin. Elevated prolactin level may be helpful in differentiating generalized tonic-clonic or complex partial seizure from psychogenic nonepileptic seizures, only if the patient’s prolactin level is measured 10 to 20 minutes after a suspected seizure event. Analysis of the serum prolactin level is not effective in distinguishing a seizure from syncope. No conclusion could be established regarding serum prolactin changes following status epilepticus, repetitive seizures, and neonatal seizures.

Laboratory Findings

The chemical panel and laboratory tests for patients with seizure may include checking for:[1]

Serum Prolactin Level

One interpretation is the "prolactin should at least double and achieve a minimum value of 15 ng/mL in order to meet criteria for marking an epileptic seizure."[2]

A meta-analysis in 2004 found that:[3]

  • If the serum prolactin level is more than three times the baseline (taken within one hour of the event and in the absence of test modifiers):
    • The patient is nine times more likely to have had a generalized tonic-clonic seizure (GTCS) compared to a pseudoseizure, and five times more likely to have had a GTCS compared to a nonconvulsive syncope.

A review by the American Academy of Neurology in 2005 found:[4]

  • For GTCS versus pseudoseizure:
    • Sensitivity: 60%
    • Specificity: 96%
  • Elevated prolactin level may be helpful in differentiating GTCS or complex partial seizure from psychogenic nonepileptic seizures, only if the patient’s prolactin level is measured 10 to 20 minutes after a suspected seizure event (grade B).
  • Analysis of the serum prolactin level is not effective in distinguishing a seizure from syncope.
  • No conclusion could be established regarding serum prolactin changes following status epilepticus, repetitive seizures, and neonatal seizures (Level U).

A cohort study in 2016 of patient in an epilepsy monitoring unit who has prolactin measured within 20 minutes found[5]:

  • For diagnosis of generalized tonic-clonic seizure (GTCS)
    • Sensitivity: 100%
    • Specificity: 81%

References

  1. Gavvala JR, Schuele SU (2016). "New-Onset Seizure in Adults and Adolescents: A Review". JAMA. 316 (24): 2657–2668. doi:10.1001/jama.2016.18625. PMID 28027373.
  2. Fisher RS (2016). "Serum prolactin in seizure diagnosis: Glass half-full or half-empty?". Neurol Clin Pract. 6 (2): 100–101. doi:10.1212/CPJ.0000000000000228. PMC 5720615. PMID 29377043.
  3. Ahmad S, Beckett MW (2004). "Value of serum prolactin in the management of syncope". Emerg Med J. 21 (2): e3. doi:10.1136/emj.2003.008870. PMC 1726305. PMID 14988379.
  4. Chen DK, So YT, Fisher RS, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (2005). "Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology. 65 (5): 668–75. doi:10.1212/01.wnl.0000178391.96957.d0. PMID 16157897.
  5. Abubakr A, Wambacq I (2016). "Diagnostic value of serum prolactin levels in PNES in the epilepsy monitoring unit". Neurol Clin Pract. 6 (2): 116–119. doi:10.1212/CPJ.0000000000000232. PMC 5720616. PMID 29377044.